pharmaceutical
Mylan looks to muscle in on Allergan’s Botox territory
March 1, 2018Sales and Marketing Botox, Mylan, Revance Therapeutics, biotech, drugs, epipen, pharma, pharmaceutical
Mylan announced, alongside its financials, that it had signed a global collaboration and licensing agreement with Revance Therapeutics to partner …
EMA set to also revise guidelines of Alzheimer’s trials
February 28, 2018Medical Communications Alzheimer's, EMA, FDA, biotech, drugs, pharma, pharmaceutical
The EMA, following on from the FDA’s lead earlier this month, has announced that it will revise its guidelines on …
Stem cell therapy offers hope for spinal cord injuries
February 28, 2018Research and Development biotech, drugs, pharma, pharmaceutical, stem cell, stem cell treatment
Scientists have brought the prospect of spinal cord injuries being able to be treated with stem cells one step closer, …
AstraZeneca creates biotech spin-off, $250m in bank
February 28, 2018Research and Development, Sales and Marketing AstraZeneca, Viela, biotech, drugs, pharma, pharmaceutical
Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely …
Generation Bio backed with $100m financing round
February 28, 2018Research and Development, Sales and Marketing Generation Bio, biotech, drugs, pharma, pharmaceutical
At the start of year, Generation Bio was revealed to the public, announcing that it had been developing gene therapies …
Allergan’s patent gamble fails
February 27, 2018Manufacturing and Production, Medical Communications Allergan, Mylan, biotech, drugs, patent, pharma, pharmaceutical
Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review …
UK govt report looks to reduce vaccination spending
February 27, 2018Manufacturing and Production, Medical Communications Vaccine, biotech, drugs, meningitis, pharma, pharmaceutical
One of the largest petitions ever to have gone before UK parliament, after it attracted 823,349 signatures, brought about the …
UK to crack down on 237m annual medication errors
February 23, 2018Medical Communications Jeremy Hunt, NHS, biotech, drugs, pharma, pharmaceutical
A new study commissioned by the Department of Health and Social Care has revealed that 237 million medication errors are …
Lab-grown tumours able to predict drug efficacy
February 23, 2018Medical Communications, Research and Development biotech, drugs, pharma, pharmaceutical
One of the key challenges facing the treatment of cancer is knowing whether a particular drug will work with an …
Gilead seals $3bn deal, hoping for off-the-shelf CAR-T
February 23, 2018Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical
The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …
AllTrials puts FDA under pressure with Trials Tracker
February 22, 2018Medical Communications alltrials, biotech, drugs, pharma, pharmaceutical
A year to the day that the FDA unveiled its Final Rule, which sees organisation given 13 months from clinical …
CDC U-turns previous decision on AZ’s flu vaccine
February 22, 2018Sales and Marketing AstraZeneca, Vaccine, biotech, drugs, flu, influenza, pharma, pharmaceutical
The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for …
Greek parliament moves to investigate 10 politicians
February 22, 2018Medical Communications, Sales and Marketing Greece, Greek Parliament, Novartis, biotech, drugs, pharma, pharmaceutical
After a 20-hour debate, Greek parliament has voted in favour of investigating 10 politicians named as part of an investigation …
AZ licenses kidney drug from Ionis for $330m
February 21, 2018Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
AbbVie turns to tau for Alzheimer’s in $1.1bn deal
February 21, 2018Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical
Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
